

# ZETA Corporation

## CD13 (ZM287) Mouse Monoclonal Antibody For In Vitro Diagnostic Use (IVD)

### Product Identification

Z2524ML	1.0 ml (Concentrate)
Z2524MS	0.5 ml (Concentrate)
Z2524MT	0.1 ml (Concentrate)
Z2524MP	7 mL (pre-dilute)

### Intended Use

This antibody is intended for *in vitro* diagnostic (IVD) use. CD13 (ZM287) Mouse Monoclonal Primary Antibody is intended for professional laboratory use in the detection of the CD13 protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing.

This antibody is intended to be used after the primary diagnosis of the tumor has been made by conventional histopathology using non-immunological histochemical stains. A qualified pathologist must interpret the results using this product as an aid to diagnosis in conjunction with the patient's relevant clinical history, other diagnostic tests, and proper controls.

### Summary and Explanation

Recognizes an integral membrane glycoprotein of 150kDa, identified as CD13 (also known as aminopeptidase-N). The antibody recognizes an extracellular epitope. The CD13 antigen is present on most cells of myeloid origin, including granulocytes, monocytes, mast cells, and GM-progenitor cells. It is also expressed by most AML and CML in myeloid blast crises and in a smaller fraction of lymphoid leukemias. CD13 is absent from normal lymphocytes, platelets, and erythrocytes. CD13 is also present on fibroblasts; endothelial cells, epithelial cells from proximal renal tubules and intestinal brush border, bone marrow stromal cells, osteoclasts, and cells lining bile duct canaliculi. CD13 is identical to aminopeptidase N (APN), a prominent membrane-bound metalloprotease present on the surface of the intestinal brush border and renal tubules. CD13 plays a role in the metabolism of biologically active peptides in phagocytosis and bactericidal/tumoricidal activities. It also serves as a receptor for human coronaviruses (HCV). The lineage-restricted pattern of expression of CD13 within the hemopoietic compartment suggests that it may be essential in myeloid cell differentiation.

### Principle of Method

CD13 (ZM287) Mouse Monoclonal antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended.

In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential

application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex, and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

### Materials Provided

CD13 (ZM287) Mouse Monoclonal in concentrated form or prediluted

#### Antibody Specifications:

The antibody as Purified antibody diluted in Tris-HCl buffer containing stabilizing protein and <0.1% ProClin.

Host: Mouse

Isotype: IgG1 / $\kappa$

Immunogen: Recombinant fragment (around aa50-250) of human ANPEP protein (exact sequence is proprietary)

Cellular Localization: Cytoplasmic

Concentrate Dilution Range: 1:100-200

Positive control: Bone marrow

### Storage and Handling

Upon receiving, store vial at 2-8°C. When stored at 2-8°C, this antibody is stable for 24 months.

To ensure proper reagent stability and functionality, the cap must be replaced, and the bottle must be placed in a refrigerator immediately in an upright position. Do not use after the expiration date stamped on the vial.

If reagents are stored under conditions other than those specified in the package insert, the user must verify them. Repeat freeze and thaw cycles may decrease antibody activity and should be avoided.

If packaging or contents appear broken or damaged, do not use and contact Zeta Corporation. Contact information is on the last page of this document.

#### Reconstitution:

Predilute Antibodies: Ready to use, no reconstitution necessary.

Concentrate Antibodies: Refer to established dilution range 1:100-200 and use appropriate lab-standardized diluent and container. Refer to the label for any specific instructions. Stability after dilution: 7 days at 24°C, three months at 2-8°C, six months at -20°C as demonstrated by stability studies performed at Zeta Corporation when using polypropylene containers.

### Materials Required but not Provided

1. Positive Tissue Control: Routinely processed, neutral-buffered formalin-fixed, paraffin-embedded Bone marrow
2. Negative control tissue (internal or external)

3. Microscope slides and coverslips
  4. Staining jars or baths
  5. Timer
  6. Xylene or xylene substitute
  7. Ethanol or reagent alcohol
  8. Deionized or distilled water
  9. Heating equipment or enzyme for tissue pretreatment step
  10. Detection system
  11. Chromogen
  12. Wash Buffer
  13. Hematoxylin
  14. Antibody diluents
  15. Peroxide Block
  16. Light Microscope
  17. Mounting medium
  18. Avidin-Biotin Blocking Reagents for use with streptavidin-biotin detection
7. When used according to instructions, this product is not classified as hazardous. The preservative in the reagent is less than 0.1% ProClin and does not meet the OSHA (USA) criteria for the hazardous substance at the stated concentration. Refer to the Safety Data Sheet (SDS) on Zeta Corporation's website.
  8. The user must validate any storage conditions other than those specified in the package insert.
  9. Diluent may contain bovine serum albumin, and supernatant may contain bovine serum. The products containing fetal bovine serum and bovine serum albumin are purchased from commercial suppliers. The certificates support that the bovine sources are from countries with negligible BSE risk and state bovine sources from the USA and Canada.
  10. As with any product derived from biological sources, proper handling procedures should be used.

## Specimen Preparation for Analysis

Routinely processed, neutral-buffered formalin-fixed and paraffin-embedded tissue section tissues are used with this primary antibody. Approximately 4µm tissue sections are preferred, and they should be placed on positively charged slides. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval is recommended. Results may vary due to prolonged fixation or unexpected foreign materials or interfering substances. Decalcification may also affect the staining results.

Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.

## Warnings and Precautions

1. Take reasonable precautions when handling reagents. Use disposable gloves and lab coats when handling suspected carcinogens or toxic materials (example: xylene).
2. Avoid contact of reagents with eyes and mucous membranes. If reagents contact sensitive areas, wash with copious amounts of water.
3. Patient specimens and all materials contacting them should be handled as biohazardous materials and disposed of with proper precautions. Never pipette by mouth.
4. The user must validate incubation times and temperatures.
5. The prediluted, ready-to-use reagents are optimally diluted, and further dilution may result in loss of antigen staining.
6. The concentrated reagents may be diluted optimally based on validation by the user. Any diluent used that is not explicitly recommended herein must likewise be validated by the user for compatibility and effect on stability.

## Quality Control Procedures

### Positive Tissue Control

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as positive and negative control tissue. External Positive control materials should be fresh autopsy/ biopsy/ surgical specimens fixed, processed, and embedded as soon as possible in the same manner as the patient sample(s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to detect subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and detecting minor reagent degradation levels.

### Negative Control Tissue

Internal or external negative control tissue may be used depending on the organization's guidelines and policies to which the end-user belongs. The variety of cell types present in many tissue sections offers internal negative control sites, but the user should verify this. The components that do not stain should demonstrate the absence of specific staining and indicate non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

### Patient Tissue

Patient specimens should be examined last. Positive staining intensity should be assessed within the context of any nonspecific background staining of the negative reagent

control. As with any immunohistochemical test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells/tissue assayed. If necessary, use a panel of antibodies to identify false-negative reactions.

## Interpretation of Results

The immunostaining procedure causes a colored reaction product to precipitate at the antigen sites localized by the primary antibody. Refer to the appropriate detection system package insert for expected color reactions. A licensed pathologist experienced in immunohistochemistry procedures must evaluate the control tissues before interpreting results.

### Positive Tissue Control

The stained positive control should be examined first to ensure that all reagents function properly. The presence of an appropriately colored reaction product within the target cells or markers indicates positive reactivity. Refer to the package insert of the detection system used for color reactions. Excessive or incomplete staining may compromise the proper interpretation of results. If positive tissue control fails to demonstrate appropriate positive staining, any results with the specimens are considered invalid.

### Negative Tissue Control

The negative tissue control (internal or external) should be examined to verify the primary antibody's specific labeling of the target antigen after the positive tissue control. The absence of specific staining in the negative tissue control confirms the lack of antibody cross-reactivity to cells or cellular components. If specific staining occurs in the negative tissue control, results with the patient specimen are considered invalid.

### Patient Tissue

Patient tissues should be examined next. Positive staining should be assessed within the context of any background staining of the (internal) negative control. As with any immunohistochemical test, a negative result means that the antigen in question was not detected, not that the antigen is absent in the cells or tissue assayed. A panel of antibodies may aid in the identification of false-negative reactions. A qualified pathologist must interpret the patient's morphologic findings and relevant clinical data.

## Limitations

1. This reagent is for professional laboratory use only as immunohistochemistry is a multiple-step process that requires specialized training in selecting the appropriate reagents, tissues, fixation, processing; preparation of the immunohistochemistry slide; and interpretation of the staining results.
2. For in vitro diagnostic use.

3. Tissue staining is dependent on the handling and processing of the tissue before staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning, or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false-negative results. Inconsistent results may result from variations in fixation and embedding methods and inherent irregularities within the tissue.
4. Excessive or incomplete counterstaining may compromise the proper interpretation of results.
5. The clinical interpretation of any positive staining, or its absence, must be evaluated within the context of clinical history, morphology, other histopathological criteria, and other diagnostic tests. This antibody is intended to be used in a panel of antibodies if applicable. A qualified pathologist's responsibility is to be familiar with the antibodies, reagents, diagnostic panels, and methods used to produce the stained preparation. Staining must be performed in a certified, licensed laboratory under the supervision of a pathologist who is responsible for reviewing the stained slides and assuring the adequacy of positive and negative controls.
6. Zeta provides antibodies in both concentrated and prediluted formats at optimal dilution for use. Please refer to Dilution Range and Reconstitution on pages 1 and 2.  
Any deviation from recommended test procedures may invalidate expected results. Appropriate controls must be employed and documented. Users in any circumstance must accept responsibility for the interpretation of patient results.
7. Zeta provides some antibodies in a concentrated format so that the user may subsequently optimally dilute for use subject to the user's determination of and adherence to suitable validation techniques. Users must validate the use of any diluents other than what is recommended herein (see Dilution Range). Users in any circumstance must accept responsibility for the interpretation of patient results.
8. Reagents may demonstrate unexpected reactions in previously untested tissues. The possibility of unforeseen reactions even in tested tissue groups cannot be eliminated because of biological variability of antigen expression in neoplasms or other pathological tissues.
9. Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.
10. When used in blocking steps, normal sera from the same animal source as the secondary antisera may cause false negative or false positive results because of autoantibodies or natural antibodies.
11. False-positive results may be seen because of the non-immunological binding of proteins or substrate reaction products. They may also be caused by pseudoperoxidase activity (erythrocytes), endogenous peroxidase activity (cytochrome C), or endogenous biotin (example: liver,

brain, breast, kidney) subject to the type of immunostaining technique used.

12. As with any immunohistochemistry test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells or tissue assayed.
13. The prediluted antibody products are optimized as ready-to-use products. Because of the possibility of variation in tissue fixation and processing, it may be necessary to increase or decrease the primary antibody incubation time on individual specimens.
14. Combined with detection systems and accessories, this antibody detects antigen(s) that survive routine formalin fixation, tissue processing, and sectioning. Users who deviate from recommended test procedures *remain, as they would in any circumstance, responsible for interpreting and validating* patient results.
15. For laboratory use only.

## Performance Characteristics

### Myeloid precursors, myeloid leukemias

Tissue Types	CD13 Positivity (%)
Precursor B-Lymphoblastic	5-8
Precursor T-Lymphoblastic	15
Acute Myeloid Leukemia	95

Reference: Chu, Peiguo, and Lawrence M Weiss. Modern Immunohistochemistry. 2<sup>nd</sup> ed., Cambridge, Cambridge University Press, 2014, pp.1-479.

The intended purpose, characteristic, and outcome of each antibody are unique, and therefore, the results of staining

should be assessed and interpreted appropriately by a licensed pathologist.

## References

1. Piedfer M, et al. FASEB J. 2011; 25:2831-42.
2. Pileri SA, et al. Leukemia. 2007; 21:340-50.
3. Rocken C, et al. J ClinPathol. 2005; 58:1069- 75.

If the user experiences any technical or performance-related issues, please consult the manufacturer or competent authority.

Any severe incident about the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Doc Number: 20210101001

Version: 72019

Date of issue: January 1, 2021

## Symbol Glossary

Symbol	Definition
<b>C</b>	Concentrate
<b>P</b>	Predilute
<b>S</b>	Supernatant
<b>DIL</b>	Dilution



Zeta Corporation  
65 N 1<sup>st</sup> Ave, Ste 202C  
Arcadia, CA 91006, USA  
Tel: (626) 355-2053  
<http://www.zeta-corp.com>



Emergo by UL  
Prinsessegracht 20  
2514 AP The Hague  
The Netherlands  
Tel: +31 70 345 8570